Cosco international Inc, maker of Carpe antiperspirant, received a Warning Letter from the US Food and Drug Administration (FDA). The Agency found significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. Because Cosco’s methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, FDA deemed its drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Dru...